Stoke Therapeutics (STOK) Competitors $13.75 -1.39 (-9.18%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STOK vs. RVNC, ARCT, HRTX, MRSN, NRIX, MOR, MORF, IDYA, KYMR, and PTGXShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Revance Therapeutics (RVNC), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), Nurix Therapeutics (NRIX), MorphoSys (MOR), Morphic (MORF), IDEAYA Biosciences (IDYA), Kymera Therapeutics (KYMR), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector. Stoke Therapeutics vs. Revance Therapeutics Arcturus Therapeutics Heron Therapeutics Mersana Therapeutics Nurix Therapeutics MorphoSys Morphic IDEAYA Biosciences Kymera Therapeutics Protagonist Therapeutics Revance Therapeutics (NASDAQ:RVNC) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Which has preferable valuation and earnings, RVNC or STOK? Stoke Therapeutics has lower revenue, but higher earnings than Revance Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevance Therapeutics$234.04M2.60-$323.99M-$3.63-1.60Stoke Therapeutics$8.78M82.45-$104.70M-$2.41-5.71 Do insiders and institutionals have more ownership in RVNC or STOK? 97.7% of Revance Therapeutics shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is RVNC or STOK more profitable? Revance Therapeutics has a net margin of -117.88% compared to Stoke Therapeutics' net margin of -683.35%. Revance Therapeutics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Revance Therapeutics-117.88% N/A -41.05% Stoke Therapeutics -683.35%-57.89%-42.22% Do analysts recommend RVNC or STOK? Revance Therapeutics presently has a consensus price target of $10.50, indicating a potential upside of 80.72%. Stoke Therapeutics has a consensus price target of $21.40, indicating a potential upside of 55.64%. Given Revance Therapeutics' higher possible upside, equities analysts clearly believe Revance Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revance Therapeutics 0 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.10Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the MarketBeat Community believe in RVNC or STOK? Revance Therapeutics received 297 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 73.76% of users gave Stoke Therapeutics an outperform vote while only 63.05% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformRevance TherapeuticsOutperform Votes40163.05% Underperform Votes23536.95% Stoke TherapeuticsOutperform Votes10473.76% Underperform Votes3726.24% Which has more risk and volatility, RVNC or STOK? Revance Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Stoke Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Does the media prefer RVNC or STOK? In the previous week, Revance Therapeutics had 10 more articles in the media than Stoke Therapeutics. MarketBeat recorded 14 mentions for Revance Therapeutics and 4 mentions for Stoke Therapeutics. Revance Therapeutics' average media sentiment score of 0.38 beat Stoke Therapeutics' score of 0.31 indicating that Revance Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revance Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRevance Therapeutics beats Stoke Therapeutics on 11 of the 18 factors compared between the two stocks. Ad DealMakerHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.Join GM as an early investor in this company by October 3. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$723.94M$7.53B$5.54B$8.43BDividend YieldN/A4.43%4.97%4.06%P/E Ratio-5.7119.15143.6618.94Price / Sales82.45356.971,661.7386.99Price / CashN/A37.7037.5031.50Price / Book3.856.004.954.56Net Income-$104.70M$152.92M$112.93M$225.36M7 Day Performance-4.98%8.02%9.20%3.33%1 Month Performance-6.53%20.92%15.54%7.82%1 Year Performance209.68%26.22%33.42%14.54% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVNCRevance Therapeutics4.4877 of 5 stars4.49 / 5 stars$6.55-0.2%$10.50+60.3%-57.6%$686.57M$234.04M-1.80597High Trading VolumeARCTArcturus Therapeutics2.8207 of 5 stars2.82 / 5 stars$20.75+4.2%$71.40+244.1%-24.6%$558.80M$169.93M-5.31180News CoverageHRTXHeron Therapeutics3.4203 of 5 stars3.42 / 5 stars$1.87+1.6%$6.00+220.9%+77.2%$283.62M$127.04M-3.07300Positive NewsMRSNMersana Therapeutics4.3236 of 5 stars4.32 / 5 stars$2.11+19.2%$6.00+184.4%+62.2%$258.86M$36.85M-1.85150News CoverageNRIXNurix Therapeutics1.142 of 5 stars1.14 / 5 stars$24.80+5.2%$27.00+8.9%+168.3%$1.22B$62.30M-8.49300Positive NewsMORMorphoSys0.1645 of 5 stars0.16 / 5 stars$18.96flat$11.78-37.9%N/A$2.86B$238.28M-5.45730MORFMorphic1.3965 of 5 stars1.40 / 5 stars$56.99flat$54.25-4.8%+8.6%$2.85B$520,000.00-16.28100IDYAIDEAYA Biosciences4.4601 of 5 stars4.46 / 5 stars$37.46+3.7%$56.20+50.0%+20.5%$2.84B$11.96M-18.6480Positive NewsKYMRKymera Therapeutics1.067 of 5 stars1.07 / 5 stars$46.08+3.0%$48.67+5.6%+161.5%$2.83B$88.55M-18.36170Insider SellingPTGXProtagonist Therapeutics2.3385 of 5 stars2.34 / 5 stars$47.02+3.0%$47.33+0.7%+159.7%$2.77B$60M19.27120 Related Companies and Tools Related Companies: RVNC Alternatives ARCT Alternatives HRTX Alternatives MRSN Alternatives NRIX Alternatives MOR Alternatives MORF Alternatives IDYA Alternatives KYMR Alternatives PTGX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STOK) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
